MP3 Catalog
mp3 archive
artists 140675
albums 351765
What's hot?
Bjork
Volta
The Pigeon Detectives
Wait for Me
Timbaland
Shock Value
Simply Red
Stay
Cascada
Everytime We Touch
Akon
Konvicted
Amy Winehouse
Back to Black
Gwen Stefani
The sweet Escape
Christina Aguilera
Back to Basics
Navigation
Search music:
Music by alphabet

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z #

artist:

Dysrhythmia


discography
 Album TitleYearInfoTypePriceBuy
Dysrhythmia No Interference

Dysrhythmia
No Interference

2005
tracks: 16
size: 116.30 Mb

cd
$ 3.20
buy No Interference

Comments For: Dysrhythmia

Hide comments

1.   SLeep     2008-05-21 04:04:47
ABILIFY(R) (aripiprazole) Receives Expanded Indications For Maintenance Treatment In Pediatric Patients With Bipolar (Medical News Today)
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced that ABILIFY® (aripiprazole) received expanded indications in Bipolar I Disorder and Schizophrenia.
2.   Kirillm     2008-05-21 04:04:47
FDA Approves AstraZeneca's Seroquel® For Maintenance Treatment In Bipolar Disorder (PharmaceuticalOnline)
AstraZeneca recently announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL (quetiapine fumarate tablets) for the maintenance treatment of patients with bipolar I disorder, as adjunct therapy to lithium or divalproex.
3.   kabernetik     2008-05-21 04:04:47
San Francisco (The San Francisco Examiner)
WILMINGTON, Del. ( Map ) - WILMINGTON, Del. , May 14 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL(R) (quetiapine fumarate tablets) for the maintenance treatment of patients with bipolar I disorder, as adjunct therapy to lithium or divalproex.
4.   akellas     2008-05-21 04:04:47
ABILIFY(R) (aripiprazole) Receives Expanded Indications for Maintenance Treatment in Both Pediatric Patients (Aged (Business Wire via Yahoo!7 Finance)
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced that ABILIFY(R) (aripiprazole) received expanded indications in Bipolar I Disorder and Schizophrenia. ABILIFY is now indicated for maintenance treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in pediatric patients (aged 10-17) and maintenance treatment
5.   liza0525     2008-05-21 04:04:47
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium or Valproate in (Business Wire via Yahoo!7 Finance)
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) approved updated labeling for ABILIFY(R) (aripiprazole) as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in adults.
6.   tanas     2008-05-21 04:04:47
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium or Valproate in (Centre Daily Times)
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) approved updated labeling for ABILIFY(R) (aripiprazole) as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder with or without psychotic features in adults. ABILIFY has
7.   forvard     2008-05-21 04:04:47
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Add-On Treatment to Lithium or Valproate in (wallstreet:online AG)
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that
8.   DROON     2008-05-21 04:04:47
San Francisco (The San Francisco Examiner)
WILMINGTON, Del. ( Map ) - WILMINGTON, Del. , May 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of generalized anxiety disorder (GAD), including maintenance of
9.   Elimas     2008-05-21 04:04:47
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the (PR Newswire via Yahoo! Finance)
AstraZeneca today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR Extended-Release Tablets to seek approval for the treatment of generalized anxiety disorder , including maintenance of antianxiety effect.
10.   Fenix006     2008-05-21 04:04:47
San Francisco (The San Francisco Examiner)
WILMINGTON, Del. ( Map ) - WILMINGTON, Del. , May 5 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN ) today announced new study data on SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adult patients.
 © 2007 www.mp33nowdownloads.com